The Four PCOS Types: Insulin, Inflammatory, Adrenal

You have a PCOS diagnosis, or you suspect one, and you keep reading about "insulin-resistant PCOS" versus "adrenal PCOS" online. You want to know which kind you have, because the internet keeps promising that picking the right type will tell you exactly what to do. The honest answer is more nuanced than the wellness blogs make it sound, and that nuance is where the actual treatment plan lives.

The four PCOS types framework (insulin-resistant, inflammatory, adrenal, and post-pill) is not in the Rotterdam criteria, the 2023 International PCOS Guideline, or any consensus document from ESHRE or ASRM.^{1 2} It is a functional-medicine lens, popularised in integrative practice, that maps the syndrome onto four different first-line interventions. I find it useful in clinic, with one rule: I use it as a starting hypothesis, not a label. Most of the people I see have a dominant driver and a secondary one, and the treatment plan reflects that mixed picture. This article walks the four lenses honestly, including where they are clinically helpful and where the evidence thins out. PCOS symptoms with insulin involvement are the most common pattern we see, so we start there.

What are the four PCOS types, and what are they not?

The four-type model groups people with PCOS by the primary biological mechanism the clinician believes is driving their syndrome. Type 1 is insulin-resistant. Type 2 is inflammatory. Type 3 is adrenal. Type 4 is post-pill. The framework was developed in integrative and naturopathic practice and brought to a wider audience by writers like Lara Briden, and it has spread through wellness blogs and PCOS communities online. It is not an official taxonomy.

The official taxonomy is Rotterdam. The Rotterdam consensus from 2003 (reaffirmed in the 2023 International PCOS Guideline) classifies PCOS into phenotypes A through D based on which of three criteria are met: clinical or biochemical hyperandrogenism, oligo- or anovulation, and polycystic ovarian morphology on ultrasound.^{1 2} Rotterdam describes what the syndrome looks like. The four-type model speculates about why. They are answering different questions.

So why use the four-type lens at all? Because in clinic, the four mechanisms map cleanly to four different first-line interventions. If insulin is the driver, the levers are metformin, inositol, resistance training, and sleep. If inflammation is the driver, the levers are vitamin D, omega-3, thyroid review, and gut work. If adrenal androgens are the driver, the levers are stress and sleep, and a careful exclusion of non-classical congenital adrenal hyperplasia before anything else. If the picture is a post-pill window, the lever is patience plus tracking. Naming the mechanism gives you a place to start.

The risk of using the framework rigidly is that a person with mixed drivers gets pushed toward a single supplement protocol, when the real answer is layered. The other risk is that "adrenal PCOS" gets confidently diagnosed without ruling out non-classical congenital adrenal hyperplasia (NCAH), which presents identically to PCOS but needs a different workup.⁴ So I treat the four-type model the way I treat any hypothesis: I let the labs and the history confirm or modify it before anything is settled.

What is insulin-resistant PCOS (Type 1)?

Insulin resistance is the most common driver. Estimates from the endocrine literature put it in 50 to 70 percent of people with PCOS, including many in a normal body-mass-index range.³ The phrase "lean PCOS with insulin resistance" is real and worth saying out loud, because a person who is not visibly overweight is often told they could not possibly be insulin resistant. They can be, and they often are.

The clinical clues sit on the body and in the labs. On the body, I look for acanthosis nigricans, the dark, velvety skin patches that appear at the nape of the neck, in the underarms, and sometimes around the knuckles. They are not dirt and they do not scrub off. I look for skin tags in the same distribution. I ask about post-meal sleepiness, sugar cravings in the afternoon, and weight that sits centrally with a waist-to-hip ratio above 0.85. In the labs, I look for a fasting insulin above 10 mIU/L, a HOMA-IR above 2.5, and a HbA1c trending into the upper end of normal.

The most sensitive single test is a 2-hour oral glucose tolerance test with insulin drawn at fasting, 60 minutes, and 120 minutes. Fasting glucose alone misses a lot of people whose post-load insulin is sky-high. I ask the lab specifically for insulin levels alongside the glucose; many labs default to glucose only unless told otherwise.

What changes outcomes for insulin-driven PCOS is reasonably well established. Metformin at 1500 to 2000 mg per day reduces hepatic glucose production and improves ovulation rates in PCOS, though the effect on live birth as monotherapy is modest. Inositol, typically myo-inositol and d-chiro-inositol in a 40:1 ratio at around 4 g per day, has meta-analytic evidence for improving menstrual regularity, ovulation rate, and markers of insulin sensitivity, with a tolerability profile better than metformin.⁵ Layered onto that, structured resistance training (two to three sessions per week), protein-forward meals to flatten glucose excursions, and consolidated sleep above seven hours per night do real metabolic work.

Why this matters for fertility: insulin drives ovarian androgen production through theca-cell signalling, and it disrupts the LH-to-FSH ratio at the pituitary. That combination is the most common reason cycles do not ovulate in PCOS. Addressing insulin upstream often unlocks ovulation that no amount of timed intercourse will reach on its own.

What is inflammatory PCOS (Type 2)?

The second proposed type is inflammatory PCOS, where chronic low-grade inflammation, often gut-derived or immune-mediated, is described as disrupting ovulation either alongside insulin resistance or independently of it. This is the type with the weakest evidence base as a discrete entity. There is good evidence that PCOS is associated with low-grade systemic inflammation generally, but whether you can carve out a distinct "inflammatory PCOS" sub-phenotype is contested.

That said, the clinical picture is recognisable. The clues are unexplained fatigue that does not lift with rest, joint aches without arthritis, irritable-bowel symptoms or chronic bloating, eczema or psoriasis, recurrent yeast infections, and labs that show an elevated high-sensitivity C-reactive protein (hs-CRP), low 25-hydroxy vitamin D, and a ferritin pattern that can sometimes look like functional iron sequestration. I also check a full thyroid panel including TPO antibodies, because autoimmune thyroid disease is common in PCOS and is its own driver of cycle disruption.

What changes outcomes is treating the inflammatory source where you can find it. Often the source is gut-related. Sometimes it is thyroid. Vitamin D repletion to a serum level of 75 to 125 nmol/L, omega-3 supplementation, and a Mediterranean-style eating pattern are the best-studied background interventions. None of these are revolutionary, but the underlying inflammation is real and worth treating regardless of whether you call it a "type" of PCOS.

The honest limit: I do not use "inflammatory PCOS" as a stand-alone diagnostic label. I treat inflammation when I find it, and I do not promise the reader that doing so will fix their cycles. Sometimes it helps. Sometimes the dominant driver is still insulin and you need to address that too.

What is adrenal PCOS (Type 3)?

In adrenal PCOS, the androgens are coming primarily from the adrenal glands rather than the ovaries. The classic biochemical signature is an elevated DHEAS with normal or only mildly elevated free testosterone and androstenedione. People with this pattern often have a thinner build, may have had a stress-onset to their symptoms, and otherwise meet Rotterdam criteria.

This is the type where I am most cautious, because there is a critical exclusion to make before assigning the label. Non-classical congenital adrenal hyperplasia, usually due to 21-hydroxylase deficiency, presents almost identically to PCOS (irregular cycles, hirsutism, acne, sometimes infertility) and requires a different workup and management.⁴ NCAH affects roughly 1 in 1000 in the general population but is markedly more common in some ancestries (Ashkenazi Jewish, Hispanic, Yugoslav, Italian populations have prevalence as high as 1 in 30 in subgroups). The screening test is a 17-hydroxyprogesterone level, drawn in the early morning and ideally in the early follicular phase, with a confirmatory ACTH stimulation test if the screening result is borderline. I rarely diagnose pure adrenal PCOS without first running a 17-OHP.

If NCAH is excluded and the pattern still looks adrenal-dominant, the levers are different from insulin-dominant PCOS. Stress reduction, sleep, and addressing chronic activation matter more than ovary-focused supplements. Some specialists use low-dose corticosteroid in selected cases, but that is specialist territory and not something to start from a wellness protocol.

A practical point: an "adrenal PCOS" label on its own, without a 17-OHP on file, is a flag for me. I will go back and ask for that test before I move forward with the treatment plan.

What is post-pill PCOS (Type 4)?

The fourth type is the one I find most useful diagnostically, because it forces a question that has to be answered honestly: was this PCOS all along, or is this the cycle finding its way back?

The combined oral contraceptive pill suppresses ovulation for the duration of use. After stopping, some people experience a 3 to 6 month window of anovulation and androgen rebound. For most, cycles re-establish themselves within six months. For a subset, they do not, and that subset divides into two: those who had PCOS that was masked by the pill, and those who have transient post-pill anovulation that will resolve given time.

The diagnostic question is which one you are. Without pre-pill cycle data, it is often impossible to tell in the first six months. The clues that point toward true underlying PCOS are a childhood history of hirsutism or acne predating the pill, polycystic ovarian morphology on ultrasound (though that finding has its own caveats, since the ovary often retains a polycystic appearance for months after the pill stops), and a family history of PCOS or insulin resistance.

What changes outcomes in the first six months is mostly patience, tracking, and basic background optimisation. I will sometimes add inositol if the picture is leaning insulin-driven. I rarely commit to a full "PCOS treatment plan" until I have watched a minimum of six to nine months of post-pill cycles, unless ovulation has been absent for more than a year or there are signs of hyperandrogenism that are not settling. Calling something PCOS prematurely closes the door on the simpler answer.

How does a clinician use the four-type lens in your visit?

When a couple sees me for a PCOS workup, the four-type model is one of three or four things I am sorting through in the first appointment. I am not trying to fit you into a box. I am trying to identify which of these mechanisms is loudest for you, because that is what changes the plan.

I start with the history. Family history of type 2 diabetes points me toward insulin biology. A history of childhood acne, hirsutism, or irregular cycles before any pill use makes a lifelong PCOS picture more likely than post-pill recovery. The pill history itself matters: what they were on, when they stopped, what the cycles looked like before. Autoimmune disease in the family, ethnicity (relevant for NCAH risk), and lifestyle exposures all factor in.

I look at the body. Skin first: acanthosis nigricans, skin tags, the distribution of hirsutism, the pattern of any scalp hair loss. Body composition broadly. I do not pin a diagnosis on a body type, but I notice the signal.

I order a full workup. The hormonal panel is LH, FSH, oestradiol, total and free testosterone, SHBG, DHEAS, 17-hydroxyprogesterone, prolactin, and TSH. The metabolic panel is fasting glucose, fasting insulin, HbA1c, a 2-hour OGTT with insulin where indicated, and a lipid panel. Inflammatory markers (hs-CRP, vitamin D, ferritin) come in if the history suggests inflammation. A transvaginal ultrasound assesses ovarian morphology and antral follicle count.

The result is a person, not a type. Most people I see have a dominant driver and a secondary one. The plan reflects that: address the loudest mechanism first with a measurable intervention, give it three months, and re-check.

How does your PCOS type change your fertility plan?

Once the dominant driver is named, the fertility plan diverges in concrete ways. These are the differences I find most important.

For an insulin-dominant pattern, I want metformin or inositol on board before or during ovulation induction. The preconception window is the time to do metabolic work (blood-sugar stability, resistance training, sleep), because it pays off both in cycle response and in pregnancy outcomes. People with insulin-resistant PCOS have a higher risk of gestational diabetes, and the same interventions reduce that risk.

For an inflammatory-dominant pattern, the cycle plan does not change dramatically, but background optimisation does. Vitamin D repletion, thyroid review including TPO antibodies, omega-3, and addressing any gut symptoms run alongside any letrozole cycle. The interventions are not flashy. They are slow building blocks.

For an adrenal-dominant pattern, the first move is to rule out NCAH. If true PCOS with an adrenal pattern is confirmed, ovarian induction with letrozole still typically works. The supportive levers are stress and sleep work, and occasionally specialist-supervised low-dose corticosteroid.

For a post-pill picture, I usually recommend a 6-month watch with tracking before assuming you need treatment, unless cycles have been absent for over a year. That patience is not denial. It is letting the system tell you what is actually happening before you commit to a plan for the wrong problem.

What's normal, and what's a red flag?

It is normal to have features of more than one type. You are not failing the framework; the framework is approximate. Mixed pictures are the rule, not the exception. If your labs show both an elevated fasting insulin and an elevated DHEAS, the answer is to treat both drivers in parallel, not to pick a winner.

There are red flags that take you out of the "PCOS workup" conversation and into a different one. A very high DHEAS (often quoted above the upper limit of normal by a meaningful margin) and a 17-OHP above 200 ng/dL flag NCAH and need an Endocrine Society confirmatory workup.⁴ Family history of CAH or membership in a higher-prevalence ancestry strengthens that flag.

Rapidly progressive hirsutism, voice deepening, clitoromegaly, or a sudden change in muscle distribution are red flags for an androgen-secreting tumour. These are rare but they are not a PCOS supplement-protocol problem. They need imaging and an androgen workup quickly. If your symptoms are escalating fast rather than slowly, ask your doctor to address that pace specifically.

What to ask before your next appointment

A short list of questions that move the workup forward.

1. "Have we checked my 17-hydroxyprogesterone to rule out non-classical congenital adrenal hyperplasia?"
2. "Can we run a fasting insulin and a 2-hour OGTT with insulin, not just glucose?"
3. "What does my LH-to-FSH ratio suggest about ovulation drive?"
4. "Given my labs, what is the dominant driver you are treating, and what is the second-line plan if it does not move in three months?"
5. "Should we screen TPO antibodies given the cycle pattern and any thyroid history?"

A clinician who is comfortable with the workup will welcome these questions. They are the questions a careful endocrinologist asks anyway.

What's next

• If you want the skin and hair side of the picture: PCOS skin, hair, and acne and what they tell you about fertility
• If you are pre-treatment and setting up the preconception window: Preconception supplement stack
• If insulin is your dominant driver and you are ready for the next layer: Inositol and metformin for PCOS
• If cycles are anovulatory and you are heading toward ovulation induction: Letrozole for PCOS overview
• If a cycle has not worked and you need to be with that for a moment: When the cycle doesn't work

Sources

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004;19(1):41-47. https://doi.org/10.1093/humrep/deh098.
3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012;33(6):981-1030. https://doi.org/10.1210/er.2011-1034.
4. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2018;103(11):4043-4088. https://doi.org/10.1210/jc.2018-01865.
5. Unfer V, Facchinetti F, Orrù B, Roseff S, Carlomagno G. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections 2017;6(8):647-658. https://doi.org/10.1530/EC-17-0243.
6. Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society 2019;3(8):1545-1573. https://doi.org/10.1210/js.2019-00078.